Positive Phase II data bolster unoprostone's promise for retinitis pigmentosa
09 May 2011
Ian Haydock
Please Login to read the full article.
09 May 2011
Ian Haydock
ian.haydock@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- ReNeuron firms up commitment to retinal diseases with Schepens Institute
- CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea
- Narrowing price gap may not make Roche's Lucentis more attractive than Eylea
- ROCK race on as Altheon takes glaucoma candidate into Phase II
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
